Table 2.
Patient characteristics extracted from the published studies.
| Ceftazidime | Cefotaxime | Meropenem | Latamoxef | Amoxicillin | |
|---|---|---|---|---|---|
| Patients | 146 | 100 | 188 | 128 | 187 |
| Samples | 203 | 185 | 780 | 165 | 224 |
| BW (kg) | 3.00 (0.740–4.65) | 1.42 (0.512–3.99) | 1.08 (0.330–4.77) | 3.10 (1.01–4.58) | 3.05 (1.04–4.60) |
| CW (kg) | 3.08 (0.900–4.50) | 1.65 (0.530–4.20) | / | 3.22 (1.00–4.60) | 3.21 (1.06–4.58) |
| GA (weeks) | 38.6 (26.0–43.4) | 31.5 (23.0–42.0) | 28.0 (23.0–40.0) | 38.3 (27.3–41.4) | 38.1 (28.3–41.4) |
| PNA (days) | 11.0 (1.00–81.0) | 9.0 (1.00–69.0) | 21.0 (1.00–92.0) | 8.00 (1.00–54.0) | 7.00 (1.00–37.0) |
| PMA (weeks) | 40.3 (26.1–47.4) | 33.0 (25.0–44.0) | 33.0 (24.0–51.0) | 39.7 (28.4–46.1) | 39.0 (28.4–46.3) |
| CREA (μmol/L) | 33.8 (8.0–201.3) | 44.0 (13.0–226.0) | / | / | 38.0 (8.80–156) |
| ALB (g/L) | 31.7 (18.4–42.0) | 27.0 (17.0–38.0) | 23 (/) | / | / |
Patient demographic characteristics and clearance values are presented as median (range).
CW: current weight; BW: birth weight; GA: gestational age; PNA: postnatal age; PMA: postmenstrual age; CREA: serum creatinine; ALB: albumin.